Lexicon Pharmaceuticals Inc (LXRX.OQ)
23 Feb 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|62||2012||Independent Chairman of the Board|
|52||2014||President, Chief Executive Officer, Director|
|52||2015||Chief Financial Officer, Executive Vice President - Corporate and Administrative Affairs|
|53||2015||Executive Vice President, Chief Medical Officer|
|63||2015||Executive Vice President - CMC and Supply Operations|
- BRIEF-Lexicon Pharmaceuticals Q4 Loss Per Share $0.27
- BRIEF-Biopharma Credit Says Enetered Into Term Loan Agreement For Up To US$200 Mln With Lexicon Pharmaceuticals
- BRIEF-Lexicon Pharmaceuticals Secures Up To $200 Million Non-Dilutive Term Loan Financing
- BRIEF-Lexicon Pharmaceuticals reports Q3 loss per share $0.29
- BRIEF-Lexicon Pharmaceuticals initiates patient dosing in a phase 1 study of LX9211